Stefan von Berg

TL;DR: AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5 and may have important applications as a tool to elucidate the role of Gsk3 in cellular signaling and possibly in Alzheimer's disease.

TL;DR: This transgenic zebrafish model may become a valuable tool for further studies of the neuropathology of dementia and be used to identify compounds targeting the TAU kinase glycogen synthase kinase 3beta (GSK3beta).

TL;DR: This work has developed highly potent and selective inhibitors of GSK3β showing cellular efficacy and blood-brain barrier penetrance that are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.

TL;DR: Zhang et al. as mentioned in this paper reported the discovery and comprehensive preclinical characterization of AZD3839, a potent and selective inhibitor of human β-Site amyloid precursor protein cleaving enzyme1 (BACE1), which was identified using fragment-based screening and structure-based design.

TL;DR: Interestingly, subchronic but not acute administration with AZD1080 reverses MK‐801‐induced deficits, measured by long‐term potentiation in hippocampal slices and in a cognitive test in mice, suggesting that reversal of synaptic plasticity deficits in dysfunctional systems requires longer term modifications of proteins downstream of GSK3β signaling.